1. 190PDResearch-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies. (23rd October 2018) Authors: Bianchini, G; Parker, J; Carey, L; Perou, C M; Sica, L; Prat, A; Pieńkowski, T; Im, Y-H; Bianchi, G V; Ling-Ming, T; Liu, M-C; Lluch, A; Semiglazov, V; de la Haba-Rodriguez, J; Oh, D-Y; Poirier, B; Pedrini, J L; Valagussa, P; Gianni, L Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 291ORibociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 patient-reported outcomes (PROs). (23rd October 2018) Authors: Harbeck, N; Villanueva, R; Franke, F; Babu, G; Wheatley-Price, P; Im, Y-H; Altundag, K; Lanoue, B; Alam, J; Chandiwana, D; Colleoni, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 37OSubgroup analysis of IMpassion130: Atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries. (24th November 2019) Authors: Iwata, H; Im, S-A; Sohn, J; Jung, K H; Im, Y-H; Lee, K S; Inoue, K; Tamura, K; Wong, A; Emens, L A; Barrios, C H; Adams, S; Schneeweiss, A; Diéras, V; Winer, E P; Chui, S Y; Henschel, V; Rugo, H S; Loi, S; Schmid, P Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 38OTalazoparib (TALA) vs physician's choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): Data from phase III EMBRACA. (24th November 2019) Authors: Lee, K-H; Kim, S-B; Sohn, J; Goodwin, A; Usari, T; Lanzalone, S; Im, Y-H Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 39ORibociclib (RIB) + non-steroidal aromatase inhibitor (NSAI) + goserelin in premenopausal Asian women with hormone-receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): Results from the randomized phase III MONALEESA-7 study. (25th November 2018) Authors: Im, S-A; Sohn, J; Tripathy, D; Chow, L; Lee, K S; Jung, K H; Babu, G; Im, Y-H; El Saghir, N; Liu, M-C; Diaz-Padilla, I; Alam, J; Kong, O; Miller, M; Lu, Y-S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 40OSafety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with advanced breast cancer (ABC): Final results from EVEREXES. (24th November 2019) Authors: Im, Y-H; Karabulut, B; Lee, K S; Adhav, A; Park, B-W; Cinkir, H Yesil; Bowles, J; Alfaro, T Delgar; Xue, H L; Kim, S-B Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Loss of transforming growth factor β signalling in the intestine contributes to tissue injury in inflammatory bowel disease. Issue 2 (1st August 2001) Authors: Hahm, K-B; Im, Y-H; Parks, T W; Park, S-H; Markowitz, S; Jung, H-Y; Green, J; Kim, S-J Journal: Gut Issue: Volume 49:Issue 2(2001) Page Start: 190 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗